R-Chop/R-Hdac and Rituximab Maintenance Results in High Complete Remission Rate, Minimal Residual Disease Negativity, and Excellent Survival in Elderly MCL Patients

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_68
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Rituximab Maintenance After Nordic Protocol (R-Maxichop/Hd-Arac/Asct) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Molecular Minimal Residual Disease Negativity and Decreased Stem Cell Mobilization Potential Predict Excellent Outcome After Autologous Transplant in NPM1 Mutant Acute Myeloid Leukemia.

Haematologica
Hematology
2019English

Prognostic Value of Prior Consolidation in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation in Minimal Residual Disease-Negative First Complete Remission

American Journal of Hematology
Hematology
2018English

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2016English

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Male Gender Is an Independent Predictor for Worse Survival and Relapse in a Large, Consecutive Cohort of Elderly DLBCL Patients Treated With R‐ CHOP

British Journal of Haematology
Hematology
2019English

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Anti-Infective Prophylaxis With Aciclovir and Cotrimoxazole Significantly Reduces the Rate of Infections and Therapy-Associated Deaths in Elderly Patients With DLBCL Undergoing R-Chop Immunochemotherapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy